Precision Business Insights
Portfolio

 

Research Reports

Pharmaceutical Drug Development Services Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025

Global Pharmaceutical Drug Development Services Market: By Molecule Type (Biological Solutions, Small Molecule Solutions, and Biosimilar Development Solutions), By Phase (Pre-Clinical, Phase I, Phase II, Phase III), By Specialty Area (Cardiovascular, Diabetes, Endocrinology, Nephrology, Immuno-Oncology, Infectious Diseases, Oncology, Rare Diseases and Orphan Drugs, Pediatrics, Neuroscience, and Others) and Geography

 

 

Global Pharmaceutical Drug Development Services Market:

The global pharmaceutical drug development services market accounted US$ XX Mn in 2018 and projected to grow at significant CAGR over 2019-2025 owing to increasing stringent regulatory framework and cost of drug development for products coupled with focus of the pharmaceutical and biopharmaceutical companies on CROs and CDMOs to reduce the cost of the development of the product are the major factors that are driving the growth of the pharmaceutical drug development services market. Moreover, Identification of lead, drug discovery, clinical trial monitoring and regulatory compliance fuels the growth of the market over the forecast period.

 

Strategic Collaborations between the Pharmaceutical Companies and Drug Development Service Providers

The pharmaceutical and biopharmaceutical companies are focusing on the strategic collaborations with the drug development service providers to avoid the stringent regulatory policies and to reduce the cost of the drug development and this is the trend that was being observed in the market. For instance, in June 2018, Syneos Health and Elligo Health Research entered into a strategic collaboration to mobilize a system of accelerated research to reach real-world patients.

 

North America Accounts the Larger Market Revenue Share in Global Pharmaceutical Drug Development Services Market

North America accounted for larger revenue share in global pharmaceutical drug development services market with significant CAGR owing to the presence of large number of prominent market players in the region and increasing adoption of eClinical solutions and rise in the use of interactive response technology in adaptive clinical trials. Asia Pacific region is expected to grow at highest CAGR owing to more number of CDMOs and CROs presence in the region.

 

Competition Assessment

Key player’s profiles in the global pharmaceutical drug development services market include:

  • Syneos Health
  • Parexel
  • IQVIA
  • Celerion
  • Piramal Pharma solutions
  • Catalent, Inc.
  • Patheon – a Thermo Fisher Company
  • Pharmaceutical Product Development, LLC.
  • Covance Inc.
  • MEDPACE

The pharmaceutical drug development services market is surging owing to strategic collaborations and acquisition to strengthen their position in the market and enhance the growth of the market. For instance, in June 2017, Thermo Fisher Scientific., the world leader in serving science has announced the acquisition of Patheon.

 

Key Findings of the Report:

 

  • Global pharmaceutical drug development services market expanding at significant CAGR over 2019 to 2025 owing to increasing demand for outsourcing to the CROs and CDMOs for drug development services.
  • Based on specialty area, oncology segment of pharmaceutical drug development services accounted for larger market revenue share in 2018 and projected gain market revenue share over the forecast period
  • Players focusing on collaboration strategies with the government to retain market position in global pharmaceutical drug development services market

 

Global Pharmaceutical Drug Development Services Market Report Description:

Global pharmaceutical drug development services market report gives comprehensive outlook on pharmaceutical drug development services across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The report on global pharmaceutical drug development services market gives historical, current, and future market sizes (US$ Mn) on the basis of molecule, phase, specialty area, and region. This report studies global pharmaceutical drug development services market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global pharmaceutical drug development services market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global pharmaceutical drug development services market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the global pharmaceutical drug development services market report include suppliers, manufacturers, marketers, policy makers, and service providers engaged in global pharmaceutical drug development services products

 

Detailed Segmentation

 

By Molecule Type  

  • Biologic Solutions
  • Small Molecule Solutions
  • Biosimilar Development Solutions

By Phase

  • Pre-Clinical
  • Phase I
  • Phase II
  • Phase III

By Specialty Area  

  • Cardiovascular
  • Diabetes, Endocrinology, and Nephrology
  • Immuno-Oncology
  • Infectious Diseases
  • Oncology
  • Rare Diseases and Orphan Drugs
  • Pediatrics
  • Neuroscience
  • Others

Geography

 

North America

  • US
  • Canada

Europe

  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
  • Poland
  • Rest of Europe

Asia-Pacific

  • Japan
  • China
  • India
  • Australia & New Zealand
  • ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
  • South Korea
  • Rest of Asia-Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Venezuela
  • Rest of Latin America

Middle East and Africa (MEA)

  • Gulf Cooperation Council (GCC) Countries
  • Israel
  • South Africa
  • Rest of MEA

 

Key Features of the Report:

 

  • The report provides granular level information about the market size, regional market share, historic market (2014-2018) and forecast (2019-2025)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
  1. Executive Summary
  2. Global Pharmaceutical Drug Development Services Market Introduction

2.1. Global Pharmaceutical Drug Development Services Market – Taxonomy

2.2. Global Pharmaceutical Drug Development Services Market –Definitions

2.2.1. By Molecule

2.2.2. By Phase

2.2.3. By Specialty Type

  1. Global Pharmaceutical Drug Development Services Market Dynamics

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Pharmaceutical Drug Development Services Market Dynamics – Factors Impact Analysis

  1. Global Pharmaceutical Drug Development Services Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025

4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

  1. Global Pharmaceutical Drug Development Services Market Forecast, By Molecule, 2014 – 2018 and Forecast, 2019 – 2025

5.1. Biologic Solutions

5.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

5.2. Small Molecule Solutions

5.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.3. Market Opportunity Analysis

5.3. Biosimilar Development Solutions

5.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.3.3. Market Opportunity Analysis

  1. Global Pharmaceutical Drug Development Services Market Forecast, By Phase, 2014 – 2018 and Forecast, 2019 – 2025

6.1. Pre-Clinical

6.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.1.3. Market Opportunity Analysis

6.2. Phase 1

6.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.2.3. Market Opportunity Analysis

6.3. Phase II

6.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.3.3. Market Opportunity Analysis

6.4. Phase III

6.4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.4.3. Market Opportunity Analysis

  1. Global Pharmaceutical Drug Development Services Market Forecast, By Specialty Type, 2014 – 2018 and Forecast, 2019 – 2025

7.1. Cardiovascular

7.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.1.3. Market Opportunity Analysis

7.2. Diabetes, Endocrinology, and Nephrology

7.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.2.3. Market Opportunity Analysis

7.3. Immuno-Oncology

7.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.3.3. Market Opportunity Analysis

7.4. Infectious Diseases

7.4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.4.3. Market Opportunity Analysis

7.5. Oncology

7.5.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.5.3. Market Opportunity Analysis

7.6. Rare Diseases and Orphan Drugs

7.6.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

7.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.6.3. Market Opportunity Analysis

7.7. Pediatrics

7.7.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

7.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.7.3. Market Opportunity Analysis

7.8. Neuroscience

7.8.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

7.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.8.3. Market Opportunity Analysis

7.9. Others

7.9.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

7.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.9.3. Market Opportunity Analysis

  1. Global Pharmaceutical Drug Development Services Market Forecast, By Region, 2014 – 2018 and Forecast, 2019 – 2025

8.1. North America

8.1.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.1.3. Market Opportunity Analysis

8.2. Europe

8.2.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.2.3. Market Opportunity Analysis

8.3. Asia Pacific

8.3.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.3.3. Market Opportunity Analysis

8.4. Latin America

8.4.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.4.3. Market Opportunity Analysis

8.5. The Middle East & Africa

8.5.1. Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025 (Revenue, USD Mn)

8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.5.3. Market Opportunity Analysis

8.6. Global Pharmaceutical Drug Development Services Market – Opportunity Analysis Index, By Product, By Application, By End User, and Region, 2019 – 2025

  1. North America Pharmaceutical Drug Development Services Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025

9.1. Molecule Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.1.1. Biologic Solutions

9.1.2. Small Molecule Solutions

9.1.3. Biosimilar Development Solutions

9.2. Phase Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.2.1. Pre-Clinical

9.2.2. Phase I

9.2.3. Phase II

9.2.4. Phase III

9.3. Specialty Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.3.1. Cardiovascular

9.3.2. Diabetes, Endocrinology, and Nephrology

9.3.3. Immuno-Oncology

9.3.4. Infectious Diseases

9.3.5. Oncology

9.3.6. Rare Diseases and Orphan Drugs

9.3.7. Pediatrics

9.3.8. Neuroscience

9.3.9. Others

9.4. Country Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.4.1. U.S.

9.4.2. Canada

9.5. North America Pharmaceutical Drug Development Services Market – Opportunity Analysis Index, By Molecule Type, By Phase, By Specialty Type, and Country, 2019 – 2025

9.6. North America Pharmaceutical Drug Development Services Market Dynamics – Trends

  1. Europe Pharmaceutical Drug Development Services Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025

10.1. Molecule Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.1. Biologic Solutions

10.1.2. Small Molecule Solutions

10.1.3. Biosimilar Development Solutions

10.2. Phase Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.2.1. Pre-Clinical

10.2.2. Phase I

10.2.3. Phase II

10.2.4. Phase III

10.3. Specialty Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.3.1. Cardiovascular

10.3.2. Diabetes, Endocrinology, and Nephrology

10.3.3. Immuno-Oncology

10.3.4. Infectious Diseases

10.3.5. Oncology

10.3.6. Rare Diseases and Orphan Drugs

10.3.7. Pediatrics

10.3.8. Neuroscience

10.3.9. Others

10.4. Country Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

10.4.1. U.K.

10.4.2. Germany

10.4.3. France

10.4.4. Italy

10.4.5. Spain

10.4.6. Russia

10.4.7. Rest of Europe

10.5. Europe Pharmaceutical Drug Development Services Market – Opportunity Analysis Index, By Molecule, By Phase, By Specialty Type, and Country, 2019 – 2025

10.6. Europe Pharmaceutical Drug Development Services Market Dynamics – Trends

  1. Asia Pacific Pharmaceutical Drug Development Services Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025

11.1. Molecule Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.1. Biologic Solutions

11.1.2. Small Molecule Solutions

11.1.3. Biosimilar Development Solutions

11.2. Phase Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.2.1. Pre-Clinical

11.2.2. Phase I

11.2.3. Phase II

11.2.4. Phase III

11.3. Specialty Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.3.1. Cardiovascular

11.3.2. Diabetes, Endocrinology, and Nephrology

11.3.3. Immuno-Oncology

11.3.4. Infectious Diseases

11.3.5. Oncology

11.3.6. Rare Diseases and Orphan Drugs

11.3.7. Pediatrics

11.3.8. Neuroscience

11.3.9. Others

11.4. Country Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

11.4.1. China

11.4.2. Japan

11.4.3. India

11.4.4. ASEAN Counties

11.4.5. Philippines

11.4.6. Rest of Asia Pacific

11.5. Asia Pacific Pharmaceutical Drug Development Services Market – Opportunity Analysis Index, By Molecule, By Phase, By Specialty Type, and Country, 2019 – 2025

11.6. Asia Pacific Pharmaceutical Drug Development Services Market Dynamics – Trends

  1. Latin America Pharmaceutical Drug Development Services Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025

12.1. Molecule Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.1. Biologic Solutions

12.1.2. Small Molecule Solutions

12.1.3. Biosimilar Development Solutions

12.2. Phase Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.2.1. Pre-Clinical

12.2.2. Phase I

12.2.3. Phase II

12.2.4. Phase III

12.3. Specialty Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.3.1. Cardiovascular

12.3.2. Diabetes, Endocrinology, and Nephrology

12.3.3. Immuno-Oncology

12.3.4. Infectious Diseases

12.3.5. Oncology

12.3.6. Rare Diseases and Orphan Drugs

12.3.7. Pediatrics

12.3.8. Neuroscience

12.3.9. Others

12.4. Country Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

12.4.1. Mexico

12.4.2. Brazil

12.4.3. Argentina

12.4.4. Chile

12.4.5. Rest of Latin America

12.5. Latin America Pharmaceutical Drug Development Services Market – Opportunity Analysis Index, By Molecule, By Phase, By Specialty Type, and Country, 2019 – 2025

12.6. Latin America Pharmaceutical Drug Development Services Market Dynamics – Trends

  1. Middle East and Africa Pharmaceutical Drug Development Services Market Analysis, 2014 – 2018 and Forecast, 2019 – 2025

13.1. Molecule Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.1. Biologic Solutions

13.1.2. Small Molecule Solutions

13.1.3. Biosimilar Development Solutions

13.2. Phase Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.2.1. Pre-Clinical

13.2.2. Phase I

13.2.3. Phase II

13.2.4. Phase III

13.3. Specialty Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.3.1. Cardiovascular

13.3.2. Diabetes, Endocrinology, and Nephrology

13.3.3. Immuno-Oncology

13.3.4. Infectious Diseases

13.3.5. Oncology

13.3.6. Rare Diseases and Orphan Drugs

13.3.7. Pediatrics

13.3.8. Neuroscience

13.3.9. Others

13.4. Country Analysis (2014 – 2018) and Forecast (2019 – 2025) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

13.4.1. GCC Countries

13.4.2. South Africa

13.4.3. Saudi Arabia

13.4.4. Turkey

13.4.5. Rest of MEA

13.5. Middle East and Africa Pharmaceutical Drug Development Services Market – Opportunity Analysis Index, By Molecule, By Phase, By Specialty Type, and Country, 2019 – 2025

13.6. Middle East and Africa Pharmaceutical Drug Development Services Market Dynamics – Trends

  1. Competition Landscape

14.1. Strategic Dashboard of Top Market Players

14.2. Company Profiles (Introduction, Financial Analysis, Key Developments, Strategies, and SWOT Analysis)

14.2.1. Syneos Health

14.2.2. Parexel

14.2.3. IQVIA

14.2.4. Celerion

14.2.5. Piramal Pharma solutions

14.2.6. Catalent, Inc.

14.2.7. Patheon – a Thermo Fisher Company

14.2.8. Pharmaceutical Product Development, LLC.

14.2.9. Covance Inc.

14.2.10. MEDPACE   

  1. Research Methodology
  2. Key Assumptions and Acronyms
$ 3,000.00$ 8,900.00
Clear selection

Select License Type

Databank $ 3,000.00
spinner
Single User $ 4,400.00
spinner
Multiple User $ 6,600.00
spinner
Corporate User $ 8,900.00
spinner
buy now spinner
FacebookTwitterLinkedinEmail

Our Clients

Testimonials